4.25
price down icon1.85%   -0.08
after-market Handel nachbörslich: 4.25
loading

Cervomed Inc Aktie (CRVO) Neueste Nachrichten

pulisher
08:50 AM

CervoMed Inc expected to post a loss of 72 cents a shareEarnings Preview - TradingView

08:50 AM
pulisher
03:35 AM

CervoMed Announces Presentations at Upcoming AD/PD™ 2026 Scientific Conference - Sahm

03:35 AM
pulisher
Mar 12, 2026

CervoMed (CRVO) to Showcase Neflamapimod Advancements at AD/PD 2 - GuruFocus

Mar 12, 2026
pulisher
Mar 12, 2026

CervoMed Announces Presentations at Upcoming AD/PD 2026 Scientific Conference - Bitget

Mar 12, 2026
pulisher
Mar 12, 2026

Lewy body dementia has no drugs. New trial data spotlight a potential treatment - Stock Titan

Mar 12, 2026
pulisher
Mar 10, 2026

CervoMed Inc neflamapimod selected by UK platform for ALS treatment assessment - Traders Union

Mar 10, 2026
pulisher
Mar 07, 2026

Is CervoMed Inc. stock a good choice for value investorsWeekly Gains Report & Short-Term Trading Opportunity Alerts - Naître et grandir

Mar 07, 2026
pulisher
Mar 06, 2026

CervoMed to Participate in Upcoming Investor Conferences - Sahm

Mar 06, 2026
pulisher
Mar 06, 2026

D. Boral Capital Reaffirms Buy Rating for CervoMed (NASDAQ:CRVO) - Defense World

Mar 06, 2026
pulisher
Mar 05, 2026

Chardan Capital Maintains Buy Rating for CRVO | CRVO Stock News - GuruFocus

Mar 05, 2026
pulisher
Mar 05, 2026

CervoMed sets 50mg dose for phase 3 dementia trial By Investing.com - Investing.com Canada

Mar 05, 2026
pulisher
Mar 04, 2026

CervoMed Finalizes Formulation and Dosing Regimen for Phase 3 Trial in Dementia with Lewy Bodies - geneonline.com

Mar 04, 2026
pulisher
Mar 04, 2026

CervoMed sets 50mg dose for phase 3 dementia trial - Investing.com Australia

Mar 04, 2026
pulisher
Mar 04, 2026

CervoMed Advances Neflamapimod With Phase 1 Completion - TipRanks

Mar 04, 2026
pulisher
Mar 04, 2026

CervoMed (CRVO) Analyst Rating Update: Buy Rating Maintained by D. Boral Capital | CRVO Stock News - GuruFocus

Mar 04, 2026
pulisher
Mar 04, 2026

Phase 3 neflamapimod dose set at 50 mg, CervoMed Inc. asserts - Traders Union

Mar 04, 2026
pulisher
Mar 04, 2026

CervoMed Inc. Announces Successful Phase 1 Study of Stable Crystal Form of Neflamapimod and Planned Phase 3 Trial Dosing Regimen for Dementia with Lewy Bodies - Quiver Quantitative

Mar 04, 2026
pulisher
Mar 04, 2026

CervoMed picks 50mg dose for dementia drug after Phase 1 study - Stock Titan

Mar 04, 2026
pulisher
Mar 04, 2026

Can CervoMed Inc reach all time highs this year2025 Earnings Impact & Safe Swing Trade Setup Alerts - baoquankhu1.vn

Mar 04, 2026
pulisher
Mar 04, 2026

Guidance Update: Can CervoMed Inc reach all time highs this year2025 Earnings Impact & Safe Swing Trade Setup Alerts - baoquankhu1.vn

Mar 04, 2026
pulisher
Mar 01, 2026

How do insiders feel about CervoMed Inc2025 Institutional Moves & Expert Curated Trade Setup Alerts - baoquankhu1.vn

Mar 01, 2026
pulisher
Feb 24, 2026

Stock Analysis: What is CervoMed Incs revenue forecastJuly 2025 Sector Moves & Weekly Chart Analysis and Guides - baoquankhu1.vn

Feb 24, 2026
pulisher
Feb 22, 2026

CRVOCervoMed Latest Stock News & Market Updates - Stock Titan

Feb 22, 2026
pulisher
Feb 20, 2026

New ALS drug neflamapimod chosen for UK platform study - ALS News Today

Feb 20, 2026
pulisher
Feb 19, 2026

CervoMed: Capital-Efficient Expansion of Neflamapimod Into ALS Platform Trial Supports Buy Rating and $20 Target - TipRanks

Feb 19, 2026
pulisher
Feb 19, 2026

CervoMed’s neflamapimod selected for UK ALS trial platform By Investing.com - Investing.com Canada

Feb 19, 2026
pulisher
Feb 18, 2026

CervoMed’s Neflamapimod Added to U.K. ALS Platform - TipRanks

Feb 18, 2026
pulisher
Feb 18, 2026

CervoMed's neflamapimod selected for UK EXPERTS-ALS; first ALS dosing expected by end of 2026 - TradingView

Feb 18, 2026
pulisher
Feb 18, 2026

Neflamapimod joins UK EXPERTS-ALS platform for ALS at CervoMed (NASDAQ: CRVO) - Stock Titan

Feb 18, 2026
pulisher
Feb 18, 2026

CervoMed (CRVO) Analyst Rating Maintained as "Buy" by D. Boral C - GuruFocus

Feb 18, 2026
pulisher
Feb 18, 2026

CervoMed’s neflamapimod selected for UK ALS trial platform - Investing.com

Feb 18, 2026
pulisher
Feb 18, 2026

CervoMed's Neflamapimod Chosen For UK EXPERTS-ALS Platform - Nasdaq

Feb 18, 2026
pulisher
Feb 18, 2026

CervoMed (CRVO) Drug Candidate Joins EXPERTS-ALS Platform - GuruFocus

Feb 18, 2026
pulisher
Feb 18, 2026

CervoMed's neflamapimod elected for inclusion in UK Experts-ALS Platform - marketscreener.com

Feb 18, 2026
pulisher
Feb 18, 2026

CervoMed Inc. Announces Inclusion of Neflamapimod in EXPERTS-ALS Platform for ALS Trial - Quiver Quantitative

Feb 18, 2026
pulisher
Feb 18, 2026

Cervomed’S Neflamapimod Elected For Inclusion In Uk Experts-Als Platform - TradingView

Feb 18, 2026
pulisher
Feb 18, 2026

CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for Amyotrophic Lateral Sclerosis - Yahoo Finance

Feb 18, 2026
pulisher
Feb 16, 2026

Will CervoMed Inc. benefit from seasonalityJuly 2025 Setups & Smart Investment Allocation Tips - mfd.ru

Feb 16, 2026
pulisher
Feb 15, 2026

Aug Summary: Is CervoMed Inc stock a good pick for beginnersWeekly Profit Recap & High Return Stock Watch Alerts - baoquankhu1.vn

Feb 15, 2026
pulisher
Feb 13, 2026

Should You Buy CervoMed Inc (CRVO) Today? Analysis, Price Targets, and 2026 Outlook. - Intellectia AI

Feb 13, 2026
pulisher
Feb 13, 2026

Form 4: Blackburn Kelly reports acquisition/exercise transactions in CRVO - Stock Titan

Feb 13, 2026
pulisher
Feb 12, 2026

Is CervoMed Inc. stock a good pick for beginnersJuly 2025 Closing Moves & Growth Focused Stock Reports - mfd.ru

Feb 12, 2026
pulisher
Feb 10, 2026

What’s the analyst consensus on CervoMed Inc.2025 Support & Resistance & High Accuracy Investment Signals - mfd.ru

Feb 10, 2026
pulisher
Feb 06, 2026

CervoMed (NASDAQ:CRVO) Upgraded at Brookline Capital Management - Defense World

Feb 06, 2026
pulisher
Feb 03, 2026

Winners Losers: Is ALCY affected by consumer sentiment2025 Macro Impact & Low Risk High Win Rate Stock Picks - baoquankhu1.vn

Feb 03, 2026
pulisher
Feb 02, 2026

Market Outlook: Is CervoMed Inc currently under institutional pressure2025 Risk Factors & Fast Gain Swing Alerts - baoquankhu1.vn

Feb 02, 2026
pulisher
Jan 29, 2026

Nasdaq Moves: Whats ACRES Commercial Realty Corps historical returnJuly 2025 Patterns & Smart Money Movement Tracker - baoquankhu1.vn

Jan 29, 2026
pulisher
Jan 28, 2026

CervoMed Inc targets breakthrough in Lewy body dementia treatment - Traders Union

Jan 28, 2026
pulisher
Jan 26, 2026

CervoMed Inc. (NASDAQ:CRVO) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Jan 26, 2026
pulisher
Jan 26, 2026

CervoMed Inc. (NASDAQ:CRVO) Given Average Rating of “Moderate Buy” by Analysts - Defense World

Jan 26, 2026
pulisher
Jan 19, 2026

Is CervoMed Inc stock good for income investorsWeekly Trade Summary & Daily Stock Trend Reports - baoquankhu1.vn

Jan 19, 2026
pulisher
Jan 17, 2026

Geopolitics Watch: Is CervoMed Inc stock a good pick for beginnersTrade Volume Report & Verified Chart Pattern Signals - baoquankhu1.vn

Jan 17, 2026
pulisher
Jan 16, 2026

Market Overview: Does Coupang Inc have pricing powerChart Signals & Expert Approved Momentum Trade Ideas - baoquankhu1.vn

Jan 16, 2026
pulisher
Jan 15, 2026

Alpha Buying: Managing Biotech Risk With Insider Clues - Benzinga

Jan 15, 2026
$45.65
price down icon 0.48%
$28.06
price down icon 1.72%
$52.56
price down icon 1.55%
$91.19
price up icon 1.21%
$139.50
price down icon 0.01%
biotechnology ONC
$284.05
price down icon 0.44%
Kapitalisierung:     |  Volumen (24h):